ArticleBrain and behavior2025
Outcomes of Stenting in Atypical Idiopathic Intracranial Hypertension Patients With Transverse Sinus Stenosis.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundVenous sinus stenting (VSS) has emerged as a novel treatment option for idiopathic intracranial hypertension (IIH) with transverse sinus stenosis (TSS). However, the efficacy of stenting in atypical IIH patients (body mass index [BMI] < 24 kg/m
methodsThe data of IIH + TSS patients who experienced conventional medical treatment failure and received VSS treatment at Beijing Tiantan Hospital in China between May 2021 and December 2022 were retrospectively reviewed in a prospectively maintained database. Baseline characteristics and periprocedural features were collected, and follow-up clinical outcomes (intracranial pressure [ICP], stent-adjacent stenosis, and symptoms and ophthalmic improvements) were compared between typical and atypical patients.
resultsData were available for 24 IIH + VSS patients. The median age was 37 years, and 95.8% were female. There were 9/24 atypical patients (37.5%). At baseline, atypical patients had milder visual field defects than typical patients did, as reflected by the mean deviation (MD) of the worse eye (median of -3.08 decibel (dB) vs. -7.63 dB, p = 0.027). Periprocedurally, 1-2 carotid self-expandable stents with 7-9 mm in length and 40-50 mm in diameter were deployed at the site of the TSS. The median follow-up duration was 12 months (range 8-22 months). At the last visit of follow-up, stenting intervention significantly decreased the ICP and grade of papilledema and improved the best corrected visual acuity in the worse eye and MD in the fellow eye in both typical and atypical patients. The clinical outcomes of typical and atypical IIH + TSS patients were not significantly different, except that the MD of the worse eye in the atypical group was greater than that in the typical group (-1.33 dB vs. -5.31 dB, p = 0.001).
conclusionsThis study indicates a considerable proportion of atypical IIH cases among IIH + TSS patients with conventional medical treatment failure. Moreover, VSS seems to be an effective and safe therapeutic modality for atypical IIH + TSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.